← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
APXT
Apex Treasury Corp
Valuation N/A
Financial Services
Price$10.15
Model IV—
P/IV—
Limited data — see page
APYX
Apyx Medical Corp
Valuation N/A
Healthcare Risk 57 · Elevated
Price$2.90
Model IV—
P/IV—
Market implies +28.5%/yr vs model +2.2% · above model
AQB
AQUABOUNTY TECHNOLOGIES INC
Valuation N/A
Basic Materials Risk 41 · Elevated
Price$1.22
Model IV—
P/IV—
Market implies +34.2%/yr vs model +8.0% · above model
AQMS
Aqua Metals, Inc.
Valuation N/A
Basic Materials Risk 33 · Moderate
Price$2.31
Model IV—
P/IV—
Market implies +53.9%/yr vs model +5.0% · above model
AQNB
ALGONQUIN POWER & UTILITIES CORP.
Valuation N/A
Utilities Risk 47 · Elevated
Price$26.20
Model IV—
P/IV—
Limited data — see page
AQST
Aquestive Therapeutics, Inc.
Valuation N/A
Healthcare Risk 55 · Elevated
Price$4.78
Model IV—
P/IV—
Market implies +47.9%/yr vs model +2.0% · above model
ARAI
Arrive AI Inc.
Valuation N/A
Technology Risk 58 · Elevated
Price$0.24
Model IV—
P/IV—
Market implies +64.2%/yr vs model +15.0% · above model
ARBB
ARB IOT Group Ltd
Valuation N/A
Technology Risk 33 · Moderate
Price$4.49
Model IV—
P/IV—
Limited data — see page
ARBE
Arbe Robotics Ltd.
Valuation N/A
Technology Risk 31 · Moderate
Price$0.78
Model IV—
P/IV—
Market implies +69.1%/yr vs model +2.0% · above model
ARBK
Argo Blockchain Plc
Valuation N/A
Financial Services Risk 27 · Moderate
Price$2.93
Model IV—
P/IV—
Limited data — see page
ARCC
ARES CAPITAL CORP
Valuation N/A
Unknown Risk 63 · High
Price$19.74
Model IV—
P/IV—
Limited data — see page
ARCI
Archimedes Tech SPAC Partners III Co.
Valuation N/A
Financial Services Risk 36 · Moderate
Price$10.10
Model IV—
P/IV—
Limited data — see page
ARCL
ARC Group Acquisition I Corp.
Valuation N/A
Financial Services
Price$10.00
Model IV—
P/IV—
Limited data — see page
ARDC
Ares Dynamic Credit Allocation Fund, Inc.
Valuation N/A
Unknown
Price$12.18
Model IV—
P/IV—
Limited data — see page
AREC
American Resources Corp
Valuation N/A
Energy Risk 34 · Moderate
Price$2.14
Model IV—
P/IV—
Market implies +55.1%/yr vs model +4.0% · above model
ARGX
ARGENX SE
Valuation N/A
Healthcare Risk 38 · Moderate
Price$990.54
Model IV—
P/IV—
Limited data — see page
ARIS
Aris Mining Corp
Valuation N/A
Basic Materials Risk 35 · Moderate
Price$19.54
Model IV—
P/IV—
Limited data — see page
ARL
AMERICAN REALTY INVESTORS INC
Valuation N/A
Real Estate Risk 29 · Moderate
Price$16.08
Model IV—
P/IV—
Market implies +22.1%/yr vs model +4.4% · above model
ARLO
Arlo Technologies, Inc.
Valuation N/A
Technology Risk 46 · Elevated
Price$13.19
Model IV—
P/IV—
Market implies +32.2%/yr vs model +7.1% · above model
ARM
ARM HOLDINGS PLC /UK
Valuation N/A
Technology Risk 56 · Elevated
Price$239.01
Model IV—
P/IV—
Market implies +71.3%/yr vs model +8.0% · above model
ARMP
Armata Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$5.38
Model IV—
P/IV—
Limited data — see page
ARQ
Arq, Inc.
Valuation N/A
Basic Materials Risk 30 · Moderate
Price$2.20
Model IV—
P/IV—
Market implies +48.5%/yr vs model +4.8% · above model
ARQQ
Arqit Quantum Inc.
Valuation N/A
Technology Risk 44 · Elevated
Price$20.05
Model IV—
P/IV—
Limited data — see page
ARTC
Art Technology Acquisition Corp.
Valuation N/A
Financial Services
Price$10.00
Model IV—
P/IV—
Limited data — see page
ARTL
ARTELO BIOSCIENCES, INC.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$5.43
Model IV—
P/IV—
Limited data — see page
ARTV
Artiva Biotherapeutics, Inc.
Valuation N/A
Healthcare Risk 38 · Moderate
Price$8.91
Model IV—
P/IV—
Market implies +116.4%/yr vs model +15.0% · above model
ARXS
Arxis, Inc.
Valuation N/A
Industrials
Price$52.45
Model IV—
P/IV—
Limited data — see page
AS
Amer Sports, Inc.
Valuation N/A
Consumer Cyclical Risk 36 · Moderate
Price$28.07
Model IV—
P/IV—
Limited data — see page
ASA
ASA Gold & Precious Metals Ltd
Valuation N/A
Unknown
Price$60.83
Model IV—
P/IV—
Limited data — see page
ASBP
Aspire Biopharma Holdings, Inc.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$8.86
Model IV—
P/IV—
Market implies +134.9%/yr vs model +15.0% · above model
ASG
LIBERTY ALL STAR GROWTH FUND INC.
Valuation N/A
Unknown
Price$5.04
Model IV—
P/IV—
Limited data — see page
ASGI
abrdn Global Infrastructure Income Fund
Valuation N/A
Unknown
Price$22.21
Model IV—
P/IV—
Limited data — see page
ASM
AVINO SILVER & GOLD MINES LTD
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$6.49
Model IV—
P/IV—
Limited data — see page
ASND
Ascendis Pharma A/S
Valuation N/A
Healthcare Risk 54 · Elevated
Price$263.52
Model IV—
P/IV—
Limited data — see page
ASPC
ASPAC III Acquisition Corp.
Valuation N/A
Financial Services
Price$10.99
Model IV—
P/IV—
Limited data — see page
ASPCR
ASPAC III Acquisition Corp.
Valuation N/A
Financial Services
Price$0.11
Model IV—
P/IV—
Limited data — see page
ASPI
ASP Isotopes Inc.
Valuation N/A
Basic Materials Risk 32 · Moderate
Price$3.31
Model IV—
P/IV—
Market implies +62.5%/yr vs model +5.0% · above model
ASPN
ASPEN AEROGELS INC
Valuation N/A
Industrials Risk 36 · Moderate
Price$4.91
Model IV—
P/IV—
Market implies +64.2%/yr vs model +8.0% · above model
ASR
SOUTHEAST AIRPORT GROUP
Valuation N/A
Industrials Risk 50 · Elevated
Price$252.10
Model IV—
P/IV—
Limited data — see page
ASST
Strive, Inc.
Valuation N/A
Financial Services Risk 34 · Moderate
Price$27.62
Model IV—
P/IV—
Market implies +42.4%/yr vs model +50.0% · below model
ASTC
ASTROTECH Corp
Valuation N/A
Healthcare Risk 33 · Moderate
Price$7.12
Model IV—
P/IV—
Market implies -6.0%/yr vs model +33.1% · below model
ASTE
ASTEC INDUSTRIES INC
Valuation N/A
Industrials Risk 50 · Elevated
Price$40.87
Model IV—
P/IV—
Market implies +29.2%/yr vs model +6.4% · above model
ASTI
Ascent Solar Technologies, Inc.
Valuation N/A
Technology Risk 31 · Moderate
Price$2.86
Model IV—
P/IV—
Market implies +105.3%/yr vs model +2.0% · above model
ASTL
Algoma Steel Group Inc.
Valuation N/A
Basic Materials Risk 54 · Elevated
Price$4.26
Model IV—
P/IV—
Limited data — see page
ASTS
AST SpaceMobile, Inc.
Valuation N/A
Communication Services Risk 58 · Elevated
Price$60.00
Model IV—
P/IV—
Market implies +73.8%/yr vs model +50.0% · above model
ASX
ASE Technology Holding Co., Ltd.
Valuation N/A
Technology Risk 42 · Elevated
Price$37.08
Model IV—
P/IV—
Limited data — see page
ASYS
AMTECH SYSTEMS INC
Valuation N/A
Industrials Risk 40 · Elevated
Price$14.91
Model IV—
P/IV—
Market implies +24.6%/yr vs model +3.0% · above model
ATAI
AtaiBeckley Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$7.35
Model IV—
P/IV—
Market implies +63.5%/yr vs model +50.0% · above model
ATCH
AtlasClear Holdings, Inc.
Valuation N/A
Financial Services Risk 31 · Moderate
Price$0.18
Model IV—
P/IV—
Market implies +26.6%/yr vs model -10.0% · above model
ATCX
ATLAS CRITICAL MINERALS Corp
Valuation N/A
Basic Materials Risk 46 · Elevated
Price$3.31
Model IV—
P/IV—
Market implies +52.9%/yr vs model +5.0% · above model
ATEX
Anterix Inc.
Valuation N/A
Communication Services Risk 42 · Elevated
Price$82.18
Model IV—
P/IV—
Market implies +44.4%/yr vs model +50.0% · below model
ATGL
Alpha Technology Group Ltd
Valuation N/A
Technology Risk 51 · Elevated
Price$5.12
Model IV—
P/IV—
Market implies +31.3%/yr vs model +15.0% · above model
ATHE
ALTERITY THERAPEUTICS LTD
Valuation N/A
Healthcare Risk 41 · Elevated
Price$4.05
Model IV—
P/IV—
Limited data — see page
ATHR
Aether Holdings, Inc.
Valuation N/A
Technology Risk 32 · Moderate
Price$3.46
Model IV—
P/IV—
Market implies +53.0%/yr vs model +2.0% · above model
ATI
ATI INC
Valuation N/A
Basic Materials Risk 39 · Moderate
Price$198.77
Model IV—
P/IV—
Market implies +48.0%/yr vs model +5.8% · above model
ATII
Archimedes Tech SPAC Partners II Co.
Valuation N/A
Financial Services Risk 29 · Moderate
Price$10.64
Model IV—
P/IV—
Limited data — see page
ATLCL
Atlanticus Holdings Corp
Valuation N/A
Financial Services Risk 40 · Elevated
Price$25.22
Model IV—
P/IV—
Market implies -48.5%/yr vs model +25.0% · below model
ATLCP
Atlanticus Holdings Corp
Valuation N/A
Financial Services Risk 42 · Elevated
Price$24.05
Model IV—
P/IV—
Market implies -49.7%/yr vs model +25.0% · below model
ATLCZ
Atlanticus Holdings Corp
Valuation N/A
Financial Services Risk 45 · Elevated
Price$25.48
Model IV—
P/IV—
Market implies -48.2%/yr vs model +25.0% · below model
ATLX
Atlas Lithium Corp
Valuation N/A
Basic Materials Risk 39 · Moderate
Price$3.03
Model IV—
P/IV—
Market implies +59.4%/yr vs model +5.0% · above model